Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.
As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.
Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.
# # #
Contact:
Media:
Shaun Mickus
Office: (908) 927-2416
smickus@its.jnj.com
Bill Foster
Cell: (908) 392-6057
wfoster@its.jnj.com
Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.
As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.
Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.
# # #
Contact:
Media:
Shaun Mickus
Office: (908) 927-2416
smickus@its.jnj.com
Bill Foster
Cell: (908) 392-6057
wfoster@its.jnj.com